Cargando…

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

BACKGROUND: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reyes-Soffer, Gissette, Pavlyha, Marianna, Ngai, Colleen, Thomas, Tiffany, Holleran, Stephen, Ramakrishnan, Rajasekhar, Karmally, Wahida, Nandakumar, Renu, Fontanez, Nelson, Obunike, Joseph, Marcovina, Santica M., Lichtenstein, Alice H., Matthan, Nirupa R., Matta, James, Maroccia, Magali, Becue, Frederic, Poitiers, Franck, Swanson, Brian, Cowan, Lisa, Sasiela, William J., Surks, Howard K., Ginsberg, Henry N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262523/ https://www.ncbi.nlm.nih.gov/pubmed/27986651 http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025253

Ejemplares similares

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
por: Reyes-Soffer, Gissette, et al.
Publicado: (2013)

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
por: Lunven, Catherine, et al.
Publicado: (2014)

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
por: Rey, Jacques, et al.
Publicado: (2016)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
por: Millar, John S., et al.
Publicado: (2017)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
por: Huang, Hui-Chun, et al.
Publicado: (2022)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort
por: Matveyenko, Anastasiya, et al.
Publicado: (2023)

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics
por: Ming, Jeffrey E, et al.
Publicado: (2017)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab
por: Villard, Elise F., et al.
Publicado: (2016)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
por: Chemello, Kévin, et al.
Publicado: (2020)

Use of hamster as a model to study diet-induced atherosclerosis
por: Dillard, Alice, et al.
Publicado: (2010)

Effect of Diets Differing in Glycemic Index and Glycemic Load on Cardiovascular Risk Factors: Review of Randomized Controlled-Feeding Trials
por: Kristo, Aleksandra S., et al.
Publicado: (2013)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
por: Kühnast, Susan, et al.
Publicado: (2014)

Plasma Metabolite Profiles Following Consumption of Animal Protein and Soybean-Based Diet in Hypercholesterolemic Postmenopausal Women
por: Huang, Neil K., et al.
Publicado: (2022)

Plasma Metabolite Response to Simple, Refined and Unrefined Carbohydrate-Enriched Diets in Older Adults—Randomized Controlled Crossover Trial
por: Huang, Neil K., et al.
Publicado: (2022)

Comparison of Plasma Metabolome Response to Diets Enriched in Soybean and Partially-Hydrogenated Soybean Oil in Moderately Hypercholesterolemic Adults-A Pilot Study
por: Huang, Neil K., et al.
Publicado: (2023)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Micronutrient status of Palestinian school children following salt and flour fortification: a cross-sectional study
por: Massad, Salwa, et al.
Publicado: (2020)

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
por: Ramanathan, Aarti, et al.
Publicado: (2016)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Changes in cholesterol homeostasis modify the response of F1B hamsters to dietary very long chain n-3 and n-6 polyunsaturated fatty acids
por: Lecker, Jaime L, et al.
Publicado: (2011)

Spillover Effects of a Family-Based Childhood Weight-Management Intervention on Parental Nutrient Biomarkers and Cardiometabolic Risk Factors
por: Matthan, Nirupa R, et al.
Publicado: (2021)

Waist-to-height ratio associated cardiometabolic risk phenotype in children with overweight/obesity
por: Ukegbu, Tochi E., et al.
Publicado: (2023)

RE: Praluent (Alirocumab)-Induced Renal Injury
por: Rosenson, Robert S., et al.
Publicado: (2017)

Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Effect of a Family-Based Intervention on Nutrient Biomarkers, Desaturase Enzyme Activities, and Cardiometabolic Risk Factors in Children with Overweight and Obesity
por: Matthan, Nirupa R, et al.
Publicado: (2019)

Manipulation of Host Diet To Reduce Gastrointestinal Colonization by the Opportunistic Pathogen Candida albicans
por: Gunsalus, Kearney T. W., et al.
Publicado: (2015)

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials
por: Ginsberg, Henry N., et al.
Publicado: (2021)

Sex‐Specific Differences in the Predictive Value of Cholesterol Homeostasis Markers and 10‐Year Cardiovascular Disease Event Rate in Framingham Offspring Study Participants
por: Matthan, Nirupa R., et al.
Publicado: (2013)

Plasma Phospholipid Fatty Acid Biomarkers of Dietary Fat Quality and Endogenous Metabolism Predict Coronary Heart Disease Risk: A Nested Case‐Control Study Within the Women's Health Initiative Observational Study
por: Matthan, Nirupa R., et al.
Publicado: (2014)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
por: East, Cara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jm3m5pnk2jnlggb7k1qs6ua32g